Total synthesis of Δ12-PGJ2, 15-deoxy-Δ12,14-PGJ2, and related compounds

Tetrahedron Letters

Volumn 45, Issue 6, 2004, Pages 1199-1202

  Acharya, Hukum P ^a   Kobayashi, Yuichi ^a  

^a TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

15 Deoxy 12,14 PGJ2; 4 Cyclopentene 1,3 diol monoacetate; Aldol reaction; Cyclopentenone; Palladium catalyst; 12 PGJ2

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 4 CYCLOPENTENE 1,3 DIOL MONOACETATE; ACETIC ACID DERIVATIVE; ACETYLENE; ALDEHYDE; CYCLOPENTENONE; DELTA12 PROSTAGLANDIN J2; METHYLMALONIC ACID; PALLADIUM; SODIUM HYDROXIDE; UNCLASSIFIED DRUG;

ALDOL REACTION; ALPHA CHAIN; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CATALYST; CHEMICAL MODIFICATION; DRUG STRUCTURE; DRUG SYNTHESIS; PROTON NUCLEAR MAGNETIC RESONANCE; STOICHIOMETRY; STRUCTURE ANALYSIS;

EID: 0742269727     PISSN: 00404039     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tetlet.2003.11.143     Document Type: Article

References (34)

1. Fitzpatrick F.A., Wynalda M.A. J. Biol. Chem. 258:1983;11713-11718.
2. Hirata Y., Hayashi H., Ito S., Kikawa Y., Ishibashi M., Sudo M., Miyazaki H., Fukushima M., Narumiya S., Hayaishi O. J. Biol. Chem. 263:1988;16619-16625.
3. Recent reports and earlier ones: Lee T.-S., Tsai H.-L., Chau L.-Y. J. Biol. Chem. 278:2003;19325-19330.
4. Oliva J.L., Perez-Sala D., Castrillo A., Martinez N., Canada F.J., Bosca L., Rojas J.M. Proc. Natl. Acad. Sci. U.S.A. 100:2003;4772-4777.
5. McClay E.F. Prostaglandins Other Lipid Mediat. 62:2000;75-90.
6. Takeda K., Ichiki T., Tokunou T., Iino N., Takeshita A. J. Biol. Chem. 276:2001;48950-48955.
7. Narumiya S., Ohno K., Fukushima M., Fujiwara M. J. Pharmacol. Exp. Ther. 242:1987;306-311.
8. Kato T., Fukushima M., Kurozumi S., Noyori R. Cancer Res. 46:1986;3538-3542.
9. Bregman M.D., Funk C., Fukushima M. Cancer Res. 46:1986;2740-2744.
10. Narumiya S., Fukushima M. J. Pharmacol. Exp. Ther. 239:1986;500-505.
11. Tontonoz P., Hu E., Spiegelman B.M. Cell. 79:1994;1147-1156.
12. Forman B.M., Tontonoz P., Chen J., Brun R.P., Spiegelman B.M., Evans R.M. Cell. 83:1995;803-812.
13. Kliewer S.A., Lenhard J.M., Willson T.M., Patel I., Morris D.C., Lehmann J.M. Cell. 83:1995;813-819.
14. Clay C.E., Namen A.M., Fonteh A.N., Atsumi G., High K.P., Chilton F.H. Prostaglandins Other Lipid Mediat. 62:2000;23-32.
15. Reviews: Bishop-Bailey D., Wray J. Prostaglandins Other Lipid Mediat. 71:2003;1-22.
16. Straus D.S., Glass C.K. Med. Res. Rev. 21:2001;185-210.
17. Dussault I., Forman B.M. Prostaglandins Other Lipid Mediat. 62:2000;1-13.
18. 2 to research groups.
19. 2 is isolated as an olefinic mixture at C(14)-(15): Maxey K.M., Hessler E., MacDonald J., Hitchingham L. Prostaglandins Other Lipid Mediat. 62:2000;15-21.
20. The synthesis, however, suffers from low efficiency in several steps: Bickley J.F., Jadhav V., Roberts S.M., Santoro M.G., Steiner A., Sutton P.W. Synlett. 2003;1170-1174.
21. Kobayashi Y., Murugesh M.G., Nakano M., Takahisa E., Usmani S.B., Ainai T. J. Org. Chem. 67:2002;7110-7123.
22. Deardorff D.R., Linde R.G. II, Martin A.M., Shulman M.J. J. Org. Chem. 54:1986;2759-2762.
23. Bestmann H.J., Stransky W., Vostrowsky O. Chem. Ber. 109:1976;1694-1700.
24. Viala J., Santelli M. Synthesis. 1988;395-397.
25. Kiyooka S., Hena M.A. J. Org. Chem. 64:1999;5511-5523.
26. Gao Y., Hanson R.M., Klunder J.M., Ko S.Y., Masamune H., Sharpless K.B. J. Am. Chem. Soc. 109:1987;6765-6780.
27. 11 the present method seems convenient with regard to the total number of steps including preparation of the aldol partner and the catalyst.
28. 8.
29. Zhu J., Yang J.-Y., Klunder A.J.H., Liu Z.-Y., Zwanenburg B. Tetrahedron. 51:1995;5847-5870.
30. Takeda K., Nakajima A., Yoshii E. Synlett. 1997;255-256.
31. Suzuki M., Kiho T., Tomokiyo K., Furuta K., Fukushima S., Takeuchi Y., Nakanishi M., Noyori R. J. Med. Chem. 41:1998;3084-3090.
32. Tius M.A., Hu H., Kawakami J.K., Busch-Petersen J. J. Org. Chem. 63:1998;5971-5976.
33. 1H NMR spectrum of 3 with that reported.
34. Corey E.J., Fuchs P.L. Tetrahedron Lett. 13:1972;3769-3772.